相关实验视频

Updated: Sep 10, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

洛拉提尼布在81岁的NSCLC患者中实现了快速的中枢神经系统反应

Akina Nigi¹, Keisuke Iwamoto¹, Hidetoshi Itani¹

¹Department of Respiratory Medicine Japanese Red Cross Ise Hospital Ise Mie Japan.

Respirology case reports

|August 27, 2025

概括

在alectinib治疗失败后,洛拉提尼布有望改善中枢神经系统 (CNS) 症状和成像.

科学领域:

癌症学
药理学

背景情况:

无细胞淋巴瘤激酶 (ALK) 阳性非小细胞肺癌 (NSCLC) 是一个不同的分子亚型.
对第一代和第二代ALK抑制剂 (如alectinib) 可能发生耐药性.
中枢神经系统 (CNS) 转移在ALK阳性NSCLC中很常见,影响预后.

研究的目的:

评估洛拉提尼布在ALK阳性NSCLC患者的疗效.
评估洛拉提尼布对中枢神经系统症状和成像检测结果的影响.
为了确定洛拉提尼布是否有效于表现下降的老年患者.

主要方法:

在alectinib失败后,用lorlatinib治疗的ALK阳性NSCLC患者的回顾性分析.
评估临床结果,包括客观反应率 (ORR) 和反应持续时间 (DoR).
评估中枢神经系统症状的解决和中枢神经系统损伤大小的变化.

主要成果:

在对alectinib不耐药的患者中,lorlatinib在中枢神经系统症状和成像方面表现出快速改善.
患者,包括表现不佳的老年人,经历了临床益处.
观察到持久的反应,表明持续的疗效.

结论:

对于ALK阳性NSCLC患者,尤其是中枢神经系统受影响的患者,洛拉提尼布是一种可行的治疗选择.
这种药物有助于快速控制症状和稳定疾病.
需要进一步的前性研究来证实这些发现.

关键词:

美国美国国家安全委员会大脑转移洛拉提尼布绩效情况

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

Published on: July 13, 2010

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...